3billion
Financials
Valuation Metrics
3billion's Market Cap is ₩1769B. At end of 2025 it was ₩5801B. Ranked #868 of 2,405 in KR market (top 36%), #400 of 1,627 on KOSDAQ (top 25%), #98 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 176.93B KRW | KR#868/2,405 Sec#98/231 |
| Revenue | 14.27B KRW | KR#2,215/2,405 Sec#167/231 |
| Net Income | 3.17B KRW | KR#1,340/2,405 Sec#93/231 |
| Total Assets | 58.71B KRW | KR#2,112/2,405 Sec#186/231 |
| Net Assets | 29.64B KRW | KR#2,171/2,405 Sec#196/231 |
| Employees | 85 | KR#1,764/2,405 Sec#144/231 |
| Value | ||
| P/E | 55.85x | KR#1,437/2,405 Sec#94/231 |
| P/B | 5.97x | KR#2,288/2,405 Sec#197/231 |
| P/S | 12.40x | KR#2,291/2,405 Sec#173/231 |
| FCF Yield | -3.31% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 10.69% | KR#559/2,405 Sec#38/231 |
| ROA | 5.40% | KR#690/2,405 Sec#58/231 |
| Op. Margin | -39.65% | KR#2,191/2,405 Sec#158/231 |
| Revenue Growth | 102.85% | KR#83/2,405 Sec#17/231 |
| Financial Health | ||
| Debt Ratio | 98.08% | KR#1,536/2,405 Sec#176/231 |
| Total Debt | 5.06B KRW | KR#1,772/2,405 Sec#169/231 |
| FCF | -5.85B KRW | KR#1,526/2,405 Sec#122/231 |
| Cash | 9.09B KRW | KR#1,741/2,405 Sec#153/231 |
| Current Ratio | 1.29x | KR#1,405/2,405 Sec#148/231 |
| Performance | ||
| 1Y Return | -39.63% | KR#1,859/2,405 Sec#157/231 |
| 1M Return | -7.95% | KR#977/2,405 Sec#90/231 |
| From 52W High | -72.34% | KR#2,127/2,405 Sec#184/231 |
| 1Y MDD | -78.32% | KR#2,239/2,405 Sec#197/231 |
| Trading | ||
| Volume | 213,652 shares | KR#346/2,405 Sec#28/231 |
| Trading Value | 1.15B KRW | KR#549/2,405 Sec#56/231 |
| Foreign Own. | 12.18% | KR#406/2,405 Sec#31/231 |
| Per Share | ||
| EPS | 100 KRW | KR#1,425/2,405 Sec#95/231 |
| BPS | 931 KRW | KR#2,311/2,405 Sec#214/231 |
Company Info
3billion was established in 2016 to revolutionize rare disease diagnosis and treatment development using artificial intelligence, listing on KOSDAQ as a technology growth company in 2024. The company offers whole genome and whole exome-based rare disease diagnostic genetic testing services powered by AI genomic interpretation technology. By launching its genetic variant interpretation software 'GEBRA' as SaaS, 3billion is building an AI drug development platform based on accumulated data and expanding its technological competitiveness. 3billion is headquartered in Gangnam-gu, Seoul Metropolitan City.